-----------------------------
-----------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
December 19, 1996
XYTRONYX, INC.
--------------------------
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-14838 36-3258753
---------------------- ----------------------------
(Commission File Number) (IRS Employer Identification Number)
6555 Nancy Ridge Drive
Suite 200
SAN DIEGO, CALIFORNIA 92121
-----------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (619) 550-3900
--------------
Item 5. Other Events.
The News Release dated December 19, 1996 announcing that the Company had
an initial closing in a private placement of equity securities to accredited
individuals and institutional investors pursuant to Regulation D under the
Securities Act of 1933, as amended, that the Company had hired Dr. H.
Laurence Shaw to serve as the Company's new Chief Executive and President,
that Jerry A. Weisbach has agreed to join the Company's Board of Officer
Directors and Scientific Advisory Board, and that David W. Golde, M.D. has
agreed to joint the Company as Chairman of the Scientific Advisory Board
filed as Exhibit 99.1 hereto, is hereby incorporated into this Report by
reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) EXHIBITS. The following exhibit accompanies this Report:
EXHIBIT
NUMBER EXHIBIT DESCRIPTION
--------- -------------------
99.1 News Release dated December 19, 1996 announcing that
the Company had an initial closing in a private
placement of equity securities to accredited
individuals and institutional investors pursuant to
Regulation D under the Securities Act of 1933, as
amended, that the Company had hired Dr. H. Laurence
Shaw to serve as the Company's new Chief Executive
Officer and President, that Jerry A. Weisbach has
agreed to join the Company's Board of Directors and
Scientific Advisory Board, and that David W. Golde,
M.D. has agreed to joint the Company as Chairman of
the Scientific Advisory Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XYTRONYX, INC.
By: /S/ LARRY O. BYMASTER
---------------------
Larry O. Bymaster
Chief Executive Officer
Date: December 27, 1996
2
INDEX TO EXHIBITS
EXHIBIT SEQUENTIALLY
NUMBER DESCRIPTION OF EXHIBIT NUMBERED PAGE
- -------- ---------------------- -------------
99.1 News Release dated December 19, 1996 announcing that
the Company had an initial closing in a private
placement of equity securities to accredited
individuals and institutional investors pursuant to
Regulation D under the Securities Act of 1933, as
amended, that the Company had hired Dr. H. Laurence
Shaw to serve as the Company's new Chief Executive
Officer and President, that Jerry A. Weisbach has
agreed to join the Company's Board of Directors and
Scientific Advisory Board, and that David W. Golde,
M.D. has agreed to joint the Company as Chairman of
the Scientific Advisory Board.
3